KalVista Pharmaceuticals, Inc.
NASDAQ:KALVBiotechnology
+$0.00 today
- Market cap
- $1.44B
- Beta
- -0.11
- P/E (TTM)
- -9.9
- EPS (TTM)
- -$2.74
Volume 4.26M
Average 3.47M
KALV Depreciation & Amortization
Non-cash expense that spreads the cost of physical and intangible assets over their useful lives.
KalVista Pharmaceuticals, Inc.NASDAQ: KALV
Depreciation & Amortization · Q4 FY2026 · quarter ended Dec 2025
Depreciation & amortization of $355K in Q4 FY2026
Q4 FY2026 depreciation & amortization was $355K. Trailing-twelve-month depreciation & amortization was $1.56M.
Context
- Depreciation & amortization amounted to 2.0% of revenue in FY2026.
- Depreciation & amortization increased in 3 of the last 3 fiscal years.
- FY2026 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly depreciation & amortization holds near $355K or moves back toward the trailing-twelve-month quarterly average of $390.63K.
Sources:Income StatementText generated from reported figures; not investment advice.
Depreciation & Amortization history
USD · from the income statement
- Latest · FY2026
- 1.45M USD
- Year-over-year change
- +54.5%
- 4-year CAGR
- +26.7%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2026 | 2025-12-31 | 1.45M | +54.5% |
| FY2025 | 2025-04-30 | 941K | +15.3% |
| FY2024 | 2024-04-30 | 816K | +13.6% |
| FY2023 | 2023-04-30 | 718K | +27.3% |
| FY2022 | 2022-04-30 | 564K | — |
Depreciation & Amortization vs competitors
How KALV compares with its peers on the latest reported figures
- KALV's LTM Dec 2025 depreciation & amortization of $1.56M is the 5th highest of the 10 companies compared; the peer median is $1.19M.
- Depreciation & amortization amounts to 1.3% of revenue for KALV, versus a peer median of 3.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $6.46M | +0.4% | +46.9% | 7.3% | |
| LTM Mar 2026 | $5.92M | -17.6% | +20.3% | 9.3% | |
| LTM Mar 2026 | $2.41M | -1.0% | +34.3% | 0.8% | |
| LTM Mar 2026 | $2.31M | +156.8% | +70.7% | 4.0% | |
| LTM Dec 2025 | $1.56M | — | — | 1.3% | |
| LTM Mar 2026 | $1.19M | -63.3% | -7.7% | 1.5% | |
| LTM Mar 2026 | $997K | +3223.3% | +83.4% | 2.0% | |
| LTM Mar 2026 | $914K | -11.7% | +0.4% | 9.2% | |
| LTM Mar 2026 | $678K | -80.7% | -39.1% | 1.2% | |
| LTM Mar 2026 | $481K | +11.1% | +11.1% | — | |
| Peer median (excluding KALV) | $1.19M | -1.0% | +20.3% | 3.0% | |
Competitors are the stored peer set for KALV. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2022 Apr 2022 | FY2023 Apr 2023 | FY2024 Apr 2024 | FY2025 Apr 2025 | FY2026 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 73.62M |
| Cost of Revenue | 0 | 0 | 86.17M | 0 | 6.08M |
| Gross Profit | 0 | 0 | (86.17M) | 0 | 67.54M |
| Gross Margin | — | — | — | — | 91.7% |
| Research & Development | 70.17M | 80.28M | 86.17M | 71.71M | 55.64M |
| Selling, General & Admin | 26.45M | 30.6M | 54.28M | 116.29M | 183.74M |
| Operating Expenses | 96.61M | 110.87M | 54.28M | 188M | 239.38M |
| Depreciation & Amortization | 564K | 718K | 816K | 941K | 1.45M |
| EBITDA | (80.75M) | (94.37M) | (134.28M) | (173.33M) | (150.62M) |
| EBITDA Margin | — | — | — | — | -204.6% |
| Operating Income | (96.61M) | (110.87M) | (140.45M) | (188M) | (171.84M) |
| Operating Margin | — | — | — | — | -233.4% |
| Interest Income | 1.09M | 2.23M | 3.9M | 6.44M | 8.68M |
| Interest Expense | 0 | 0 | 0 | 5.79M | 19.34M |
| Other Income / Expenses | 14.27M | 17.96M | 5.35M | 7.94M | 420K |
| Income Before Tax | (82.34M) | (92.91M) | (135.1M) | (180.05M) | (171.42M) |
| Pre-Tax Margin | — | — | — | — | -232.9% |
| Income Tax Expense | 0 | 0 | (8.45M) | 3.39M | (7.13M) |
| Net Income | (82.34M) | (92.91M) | (126.64M) | (183.44M) | (164.29M) |
| Net Margin | — | — | — | — | -223.2% |
| EPS (Basic) | (3.36) | (3.33) | (3.44) | (3.69) | (3.23) |
| EPS (Diluted) | (3.36) | (3.33) | (3.44) | (3.69) | (3.23) |
| Weighted Avg Shares | 24.47M | 27.89M | 36.79M | 49.65M | 50.9M |
| Weighted Avg Shares (Diluted) | 24.47M | 27.89M | 36.79M | 49.65M | 50.9M |
KalVista Pharmaceuticals, Inc.
NASDAQ:KALV
Intrinsic Alpha fair value
Locked
Current Price
$27.00
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.